| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 10 | 2024 | 403 | 3.950 |
Why?
|
| Neoplastic Stem Cells | 9 | 2024 | 163 | 2.520 |
Why?
|
| Myelodysplastic Syndromes | 5 | 2023 | 361 | 2.500 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 2023 | 802 | 1.910 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 54 | 1.810 |
Why?
|
| Antineoplastic Agents | 10 | 2024 | 2337 | 1.480 |
Why?
|
| Mutation | 11 | 2024 | 4184 | 1.240 |
Why?
|
| Neoplasms, Second Primary | 2 | 2021 | 240 | 1.200 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2024 | 2523 | 1.110 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2024 | 610 | 1.090 |
Why?
|
| Behcet Syndrome | 3 | 2015 | 15 | 1.070 |
Why?
|
| Cyclophosphamide | 4 | 2023 | 303 | 1.000 |
Why?
|
| Clonal Evolution | 3 | 2021 | 16 | 0.950 |
Why?
|
| Cisplatin | 4 | 2024 | 599 | 0.950 |
Why?
|
| Cell Self Renewal | 4 | 2019 | 20 | 0.900 |
Why?
|
| Neoplasm, Residual | 3 | 2022 | 185 | 0.860 |
Why?
|
| Vincristine | 2 | 2020 | 108 | 0.820 |
Why?
|
| CD55 Antigens | 2 | 2024 | 21 | 0.810 |
Why?
|
| Rituximab | 2 | 2020 | 120 | 0.790 |
Why?
|
| Hematologic Neoplasms | 2 | 2023 | 354 | 0.790 |
Why?
|
| Prednisone | 2 | 2020 | 254 | 0.780 |
Why?
|
| Biomarkers, Tumor | 6 | 2021 | 1550 | 0.750 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 594 | 0.740 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2023 | 914 | 0.710 |
Why?
|
| Graft vs Host Disease | 1 | 2023 | 362 | 0.710 |
Why?
|
| Prognosis | 15 | 2024 | 3810 | 0.710 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2023 | 309 | 0.680 |
Why?
|
| Humans | 52 | 2024 | 90569 | 0.670 |
Why?
|
| Leukemia, Myeloid | 1 | 2021 | 249 | 0.670 |
Why?
|
| Adult | 21 | 2024 | 26940 | 0.620 |
Why?
|
| Splicing Factor U2AF | 1 | 2018 | 5 | 0.600 |
Why?
|
| Genomics | 2 | 2021 | 784 | 0.590 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2018 | 37 | 0.590 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2018 | 60 | 0.580 |
Why?
|
| Aged | 17 | 2024 | 19404 | 0.560 |
Why?
|
| Leukocyte Count | 1 | 2017 | 224 | 0.560 |
Why?
|
| Neutropenia | 2 | 2015 | 216 | 0.550 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 281 | 0.540 |
Why?
|
| Neoplasms | 4 | 2023 | 3029 | 0.520 |
Why?
|
| Molecular Biology | 1 | 2016 | 89 | 0.490 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 175 | 0.490 |
Why?
|
| Young Adult | 8 | 2024 | 6425 | 0.490 |
Why?
|
| Genes, Reporter | 1 | 2016 | 274 | 0.490 |
Why?
|
| Biological Factors | 1 | 2015 | 18 | 0.480 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 203 | 0.480 |
Why?
|
| Endometrial Neoplasms | 1 | 2017 | 208 | 0.470 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2014 | 21 | 0.460 |
Why?
|
| Suicidal Ideation | 1 | 2015 | 74 | 0.460 |
Why?
|
| Phenotype | 2 | 2022 | 2471 | 0.450 |
Why?
|
| Ovarian Neoplasms | 4 | 2024 | 776 | 0.450 |
Why?
|
| Middle Aged | 18 | 2024 | 26327 | 0.450 |
Why?
|
| Male | 23 | 2024 | 42931 | 0.440 |
Why?
|
| Histiocytic Disorders, Malignant | 1 | 2013 | 3 | 0.440 |
Why?
|
| Disease-Free Survival | 5 | 2020 | 1170 | 0.430 |
Why?
|
| Female | 26 | 2024 | 46855 | 0.430 |
Why?
|
| Diabetes Complications | 1 | 2014 | 172 | 0.420 |
Why?
|
| Genetic Variation | 1 | 2019 | 1382 | 0.420 |
Why?
|
| Treatment Outcome | 11 | 2024 | 8373 | 0.410 |
Why?
|
| Adolescent | 8 | 2024 | 9353 | 0.380 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2023 | 194 | 0.380 |
Why?
|
| Sarcoma | 1 | 2013 | 217 | 0.380 |
Why?
|
| Cell Line, Tumor | 7 | 2024 | 2607 | 0.370 |
Why?
|
| Cell Nucleus | 2 | 2024 | 605 | 0.370 |
Why?
|
| Tumor Microenvironment | 3 | 2020 | 478 | 0.370 |
Why?
|
| Aged, 80 and over | 9 | 2024 | 6812 | 0.360 |
Why?
|
| Bone Marrow | 2 | 2023 | 446 | 0.350 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2019 | 854 | 0.340 |
Why?
|
| Immunophenotyping | 2 | 2021 | 218 | 0.340 |
Why?
|
| Dendritic Cells | 1 | 2013 | 451 | 0.330 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 2 | 2021 | 21 | 0.320 |
Why?
|
| Leukemia | 2 | 2022 | 320 | 0.320 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2014 | 566 | 0.320 |
Why?
|
| Nanog Homeobox Protein | 3 | 2018 | 7 | 0.320 |
Why?
|
| Disease Management | 2 | 2020 | 332 | 0.300 |
Why?
|
| Risk Factors | 6 | 2024 | 5580 | 0.270 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 1708 | 0.270 |
Why?
|
| Azacitidine | 2 | 2023 | 148 | 0.250 |
Why?
|
| Signal Transduction | 3 | 2023 | 3426 | 0.240 |
Why?
|
| Survival Rate | 2 | 2020 | 1899 | 0.240 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2023 | 131 | 0.230 |
Why?
|
| CD47 Antigen | 1 | 2024 | 23 | 0.230 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2024 | 60 | 0.220 |
Why?
|
| Retrospective Studies | 5 | 2024 | 9323 | 0.220 |
Why?
|
| bcl-X Protein | 1 | 2023 | 53 | 0.220 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2023 | 37 | 0.220 |
Why?
|
| Aniline Compounds | 1 | 2023 | 59 | 0.220 |
Why?
|
| Aminopyridines | 1 | 2023 | 41 | 0.220 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2024 | 92 | 0.220 |
Why?
|
| Triazines | 1 | 2023 | 54 | 0.220 |
Why?
|
| Pyrazines | 1 | 2023 | 91 | 0.210 |
Why?
|
| Australia | 1 | 2023 | 102 | 0.210 |
Why?
|
| Mice, SCID | 3 | 2018 | 260 | 0.200 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 104 | 0.200 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2023 | 2364 | 0.200 |
Why?
|
| BRCA1 Protein | 1 | 2023 | 205 | 0.200 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2022 | 31 | 0.200 |
Why?
|
| Histones | 1 | 2024 | 344 | 0.190 |
Why?
|
| Lymphoma, T-Cell | 1 | 2022 | 58 | 0.190 |
Why?
|
| Sulfonamides | 1 | 2024 | 320 | 0.190 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2021 | 34 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2024 | 419 | 0.190 |
Why?
|
| Chromatin | 1 | 2024 | 408 | 0.190 |
Why?
|
| Activin Receptors, Type II | 1 | 2020 | 9 | 0.180 |
Why?
|
| Thrombopoietin | 1 | 2020 | 12 | 0.180 |
Why?
|
| Chromosome Aberrations | 2 | 2019 | 384 | 0.180 |
Why?
|
| Lymphoma, B-Cell | 1 | 2022 | 110 | 0.180 |
Why?
|
| Hematinics | 1 | 2020 | 11 | 0.180 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2020 | 19 | 0.180 |
Why?
|
| Naphthyridines | 1 | 2021 | 27 | 0.180 |
Why?
|
| Idarubicin | 1 | 2020 | 8 | 0.180 |
Why?
|
| Mutation Rate | 1 | 2021 | 49 | 0.180 |
Why?
|
| Receptors, Fc | 1 | 2020 | 32 | 0.180 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2021 | 49 | 0.180 |
Why?
|
| Lymphoma | 1 | 2022 | 268 | 0.180 |
Why?
|
| Symptom Assessment | 1 | 2020 | 68 | 0.180 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 232 | 0.180 |
Why?
|
| Neoplasm Transplantation | 2 | 2018 | 397 | 0.170 |
Why?
|
| Thy-1 Antigens | 1 | 2019 | 16 | 0.170 |
Why?
|
| Adenine | 1 | 2020 | 88 | 0.170 |
Why?
|
| Cytarabine | 1 | 2020 | 220 | 0.170 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 200 | 0.170 |
Why?
|
| Blood Transfusion | 1 | 2020 | 171 | 0.170 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 842 | 0.170 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 186 | 0.170 |
Why?
|
| Anemia | 1 | 2020 | 133 | 0.170 |
Why?
|
| Recurrence | 1 | 2022 | 1162 | 0.160 |
Why?
|
| Age Factors | 2 | 2024 | 1871 | 0.160 |
Why?
|
| Flow Cytometry | 1 | 2021 | 695 | 0.160 |
Why?
|
| Piperidines | 1 | 2020 | 163 | 0.160 |
Why?
|
| DNA Damage | 1 | 2021 | 374 | 0.160 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2020 | 160 | 0.160 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2020 | 565 | 0.160 |
Why?
|
| Animals | 9 | 2024 | 27692 | 0.160 |
Why?
|
| DNA Methylation | 1 | 2023 | 666 | 0.150 |
Why?
|
| Turkey | 2 | 2015 | 21 | 0.150 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2018 | 31 | 0.150 |
Why?
|
| Mice | 6 | 2024 | 11933 | 0.140 |
Why?
|
| Child | 4 | 2024 | 7216 | 0.140 |
Why?
|
| Drugs, Investigational | 1 | 2017 | 38 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2017 | 78 | 0.140 |
Why?
|
| Retreatment | 1 | 2017 | 107 | 0.140 |
Why?
|
| Smoking | 1 | 2021 | 627 | 0.140 |
Why?
|
| Apoptosis | 1 | 2023 | 1723 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 589 | 0.140 |
Why?
|
| Total Quality Management | 1 | 2016 | 33 | 0.140 |
Why?
|
| Connexins | 1 | 2018 | 202 | 0.130 |
Why?
|
| Doxorubicin | 1 | 2017 | 293 | 0.130 |
Why?
|
| Efficiency, Organizational | 1 | 2016 | 59 | 0.130 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 3692 | 0.130 |
Why?
|
| Embryonic Stem Cells | 1 | 2016 | 82 | 0.120 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1607 | 0.120 |
Why?
|
| Remission Induction | 1 | 2017 | 745 | 0.120 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2018 | 176 | 0.120 |
Why?
|
| Polyendocrinopathies, Autoimmune | 1 | 2015 | 3 | 0.120 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2015 | 8 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 792 | 0.120 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 98 | 0.120 |
Why?
|
| Cadherins | 1 | 2015 | 164 | 0.110 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 360 | 0.110 |
Why?
|
| Age of Onset | 1 | 2015 | 319 | 0.110 |
Why?
|
| Cost of Illness | 1 | 2015 | 149 | 0.110 |
Why?
|
| Biomarkers | 1 | 2020 | 1797 | 0.110 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 387 | 0.110 |
Why?
|
| Infertility, Male | 1 | 2013 | 26 | 0.110 |
Why?
|
| Linear Models | 1 | 2015 | 422 | 0.110 |
Why?
|
| Comorbidity | 1 | 2017 | 955 | 0.110 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2013 | 18 | 0.110 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 337 | 0.110 |
Why?
|
| Immunocompetence | 1 | 2013 | 26 | 0.110 |
Why?
|
| beta Catenin | 1 | 2015 | 267 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2015 | 1873 | 0.110 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2013 | 24 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1935 | 0.110 |
Why?
|
| Cross-Sectional Studies | 2 | 2017 | 1735 | 0.110 |
Why?
|
| United States | 2 | 2024 | 7142 | 0.110 |
Why?
|
| Infertility, Female | 1 | 2013 | 96 | 0.110 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2013 | 86 | 0.100 |
Why?
|
| Propranolol | 1 | 2013 | 43 | 0.100 |
Why?
|
| Back Pain | 1 | 2013 | 43 | 0.100 |
Why?
|
| Thoracic Vertebrae | 1 | 2013 | 51 | 0.100 |
Why?
|
| Prostatic Neoplasms | 2 | 2015 | 1751 | 0.100 |
Why?
|
| Spinal Neoplasms | 1 | 2013 | 49 | 0.100 |
Why?
|
| Hemangioma | 1 | 2013 | 64 | 0.100 |
Why?
|
| Transcription Factors | 2 | 2023 | 1673 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2016 | 459 | 0.100 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2013 | 106 | 0.100 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2013 | 86 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2018 | 4345 | 0.100 |
Why?
|
| Tumor Burden | 1 | 2013 | 316 | 0.100 |
Why?
|
| Clone Cells | 2 | 2023 | 215 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 1357 | 0.090 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2013 | 267 | 0.090 |
Why?
|
| Depression | 1 | 2015 | 518 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 1286 | 0.090 |
Why?
|
| Carcinoma | 1 | 2013 | 438 | 0.080 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 1695 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 1882 | 0.080 |
Why?
|
| Time Factors | 2 | 2015 | 5365 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 1182 | 0.070 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 2667 | 0.070 |
Why?
|
| Quality of Life | 1 | 2015 | 1688 | 0.070 |
Why?
|
| Philadelphia Chromosome | 1 | 2024 | 42 | 0.060 |
Why?
|
| Thymocytes | 1 | 2023 | 31 | 0.060 |
Why?
|
| Infant | 2 | 2024 | 3183 | 0.050 |
Why?
|
| Methylation | 1 | 2024 | 272 | 0.050 |
Why?
|
| Germ Cells | 1 | 2023 | 130 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2024 | 3765 | 0.050 |
Why?
|
| Thymus Gland | 1 | 2023 | 197 | 0.050 |
Why?
|
| BRCA2 Protein | 1 | 2023 | 161 | 0.050 |
Why?
|
| Protein Transport | 1 | 2024 | 426 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2024 | 491 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2023 | 177 | 0.050 |
Why?
|
| Hematopoiesis | 1 | 2023 | 169 | 0.050 |
Why?
|
| Myeloproliferative Disorders | 1 | 2024 | 135 | 0.050 |
Why?
|
| World Health Organization | 1 | 2022 | 108 | 0.050 |
Why?
|
| Uridine | 1 | 2021 | 57 | 0.050 |
Why?
|
| Germ-Line Mutation | 1 | 2023 | 349 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2024 | 381 | 0.040 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 437 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2023 | 651 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 307 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2022 | 521 | 0.040 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2019 | 36 | 0.040 |
Why?
|
| Protein Biosynthesis | 1 | 2021 | 390 | 0.040 |
Why?
|
| Connexin 26 | 1 | 2018 | 18 | 0.040 |
Why?
|
| Mammary Glands, Human | 1 | 2018 | 24 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2018 | 117 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 1499 | 0.040 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2017 | 39 | 0.040 |
Why?
|
| Karyotype | 1 | 2017 | 34 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2023 | 1547 | 0.040 |
Why?
|
| Drug Approval | 1 | 2017 | 65 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2017 | 135 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 2335 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2017 | 167 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2017 | 152 | 0.030 |
Why?
|
| Organizational Case Studies | 1 | 2016 | 28 | 0.030 |
Why?
|
| Time-Lapse Imaging | 1 | 2016 | 21 | 0.030 |
Why?
|
| Workflow | 1 | 2016 | 81 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 199 | 0.030 |
Why?
|
| Workload | 1 | 2016 | 130 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2015 | 47 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2016 | 309 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 692 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2016 | 368 | 0.030 |
Why?
|
| Familial Mediterranean Fever | 1 | 2013 | 4 | 0.030 |
Why?
|
| Syndrome | 1 | 2015 | 452 | 0.030 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2013 | 25 | 0.030 |
Why?
|
| Alleles | 1 | 2017 | 1138 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 524 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 126 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 961 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2015 | 475 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 377 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2016 | 2033 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2013 | 304 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 1251 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 1806 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 2424 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 2018 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 3486 | 0.010 |
Why?
|